|Videos|March 16, 2018

What's the Strongest Approach for Treating Pseudomonas Infections?

Marin H. Kollef, MD, discusses the strongest approach for treating Pseudomonas infections.

Marin H. Kollef, MD, professor of medicine and Virginia E. & Sam J. Golman chair of the Respiratory Intensive Care department of Washington University School of Medicine, stresses the importance of getting the therapy right in the beginning when it comes to the treatment of Pseudomonas infections. Another important aspect of Pseudomonas treatment is getting the dose right, according to Dr. Kollef; picking the right drug at the right concentration is key.


Related to this article

How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.